Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

FDA approves new hypertension drug months after Idorsia reacquired rights for $343M

Aprocitentan, sold under the brand name Tryvio, is approved for patients with high blood pressure who are already taking other antihypertensive drugs. 

too much niacin, also known as vitamin b3, may increase the risk of adverse cardiovascular events such as heart attacks and strokes.

Too much niacin? Excess vitamin B3 may increase risk of heart attack, stroke

Nutritionists view niacin, also known as vitamin B3, as a fundamental part of any diet. Consuming too much, however, could potentially be bad for the heart. 

semaglutide wegovy Novo Nordisk major adverse cardiovascular events

A big win for Wegovy: Weight loss drug semaglutide first in history to gain FDA approval for reducing heart risks

The FDA made a special announcement about its decision, describing the news as "a major advance for public health."

Thumbnail

Some older patients taking aspirin to prevent CVD may be doing more harm than good

“Aspirin is no longer a one-size-fits-all preventive tool for older adults," according to one specialist with Michigan Medicine. 

Insurance plans still denying more claims for PCSK9 inhibitors than other cardiovascular drugs

Despite an expanded indication from the FDA and lower prices, patient access to these cholesterol-lowering medications remains a significant issue.

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

Anticoagulants after TAVR: 5-year survival data favor DOACs over VKAs

However, that one finding does not tell the whole story. Researchers also found that DOACs may increase a TAVR patient's risk of a disabling stroke.

Michael Garshick, MD, director of the cardio-rheumatology program, cardiologist and assistant professor, Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, explains the role of inflammation in coronary disease development and how this risk factor can be detected and treated.

Targeting coronary inflammation helps cardiologists provide better care

Michael Garshick, MD, examines the role of inflammation in coronary disease development, detailing how this risk factor can be detected and treated.

Thumbnail

AI-powered risk score predicts how heart failure patients will respond to loop diuretics

New research out of Texas could go a long way toward improving care for patients with acute decompensated heart failure.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup